The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China

被引：7

作者：

Cui, Jiujie ^{[1
]}

Fu, Qihan ^{[2
]}

Chen, Xiaobing ^{[3
]}

Wang, Yanling ^{[1
]}

Li, Qi ^{[4
]}

Wang, Feng ^{[5
]}

Li, Zhihua ^{[6
]}

Dai, Guanghai ^{[7
]}

Wang, Yusheng ^{[8
]}

Zhang, Hongmei ^{[9
]}

Liang, Houjie ^{[10
]}

Zhou, Jun ^{[11
]}

Yang, Liu ^{[12
]}

Wang, Fenghua ^{[13
]}

Zheng, Leizhen ^{[14
]}

Chen, Xiaofeng ^{[15
]}

Gong, Ping ^{[16
]}

Liu, Jiang ^{[17
]}

Yuan, Ying ^{[18
]}

Wang, Lin ^{[19
]}

Cheng, Yuejuan ^{[20
]}

Zhang, Jun ^{[21
]}

Zhou, Yuhong ^{[22
]}

Guo, Weijian ^{[23
]}

Zhan, Xianbao ^{[24
]}

Zou, Zhengyun ^{[25
]}

Li, Da ^{[26
]}

Zeng, Shan ^{[27
]}

Li, Enxiao ^{[28
]}

Li, Zhiwei ^{[29
]}

Teng, Zan ^{[30
]}

Cao, Dan ^{[31
]}

Kan, Jie ^{[32
]}

Xiong, Jianping ^{[33
]}

Quan, Ming ^{[34
]}

Yao, Jiayu ^{[1
]}

Yang, Haiyan ^{[1
]}

Wang, Liwei ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Med Oncol, Shanghai, Peoples R China

[2] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Med Oncol, Hangzhou, Peoples R China

[3] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China

[4] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Med Oncol, Shanghai, Peoples R China

[5] Zhengzhou Univ, Affiliated Hosp 1, Dept Nucl Med, Zhengzhou, Peoples R China

[6] Sun Yat Sen Univ, Dept Med Oncol, Sun Yat Sen Med Hosp, Guangzhou, Peoples R China

[7] Chinese Peoples Liberat Army Gen Hosp, Med Oncol, Beijing, Peoples R China

[8] Affiliated Shanxi Med Univ, Shanxi Prov Canc Hosp, Dept Gastrointestinal Oncol, Taiyuan, Peoples R China

[9] Air Force Med Univ, Xijing Hosp, Dept Clin Oncol, Xian, Peoples R China

[10] Third Mil Med Univ, Army Mil Med Univ, Southwest Canc Ctr, Southwest Hosp, Chongqing 400038, Peoples R China

[11] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China

[12] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Dept Med Oncol,Canc Ctr, Hangzhou, Peoples R China

[13] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China

[14] Shanghai Jiao Tong Univ, Xin Hua Hosp, Sch Med, Oncol Dept, Shanghai, Peoples R China

[15] Nanjing Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Nanjing, Peoples R China

[16] Shihezi Univ, Affiliated Hosp 1, Sch Med, Dept Stomatol, Shihezi, Peoples R China

[17] Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept Oncol, Xinjiang, Peoples R China

[18] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[19] Hainan Genderal Hosp, Dept Med Oncol, Haikou, Peoples R China

[20] Peking Union Med Coll Hosp, Div Med Oncol, Beijing, Peoples R China

[21] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Oncol, Shanghai, Peoples R China

[22] Fudan Univ, Shanghai Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China

[23] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China

[24] Navy Med Univ, Changhai Hosp Shanghai, Dept Med Oncol, Shanghai, Peoples R China

[25] Nanjing Univ, Comprehens Canc Ctr Drum Tower Hosp, Med Sch Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China

[26] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Med Oncol, Hangzhou, Peoples R China

[27] Xiangya Hosp Cent South Univ, Dept Med Oncol, Changsha, Peoples R China

[28] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Peoples R China

[29] Harbin Med Univ, Canc Hosp, Dept Gastrointestinal Med Oncol, Harbin, Peoples R China

[30] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Peoples R China

[31] Sichuan Univ, West China Hosp, Dept Med Oncol, Chengdu, Peoples R China

[32] Qinghai Prov Peoples Hosp, Dept Med Oncol, Xining, Peoples R China

[33] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang, Peoples R China

[34] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China

来源：

JOURNAL OF PANCREATOLOGY | 2024年 / 7卷 / 01期

关键词：

Advanced pancreatic cancer; China Pancreas Data Center; Chinese; First-line regimens; Real-world study; PHASE-III TRIAL; SERUM CEA; GEMCITABINE; RISK; STATISTICS; SURVIVAL; CA19-9; LIVER; CHOLELITHIASIS; EPIDEMIOLOGY;

D O I：

10.1097/JP9.0000000000000155

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Objective:Real-world diagnostic and treatment data for pancreatic cancer in China are lacking. As such, the present study investigated the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer (including locally advanced and metastatic disease) in the Hospital-based Advanced Pancreatic Cancer Cohort in China of the China Pancreas Data Center database.Methods:A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a database. The entire course of real-world pancreatic cancer management was analyzed.Results:The proportion of patients with advanced pancreatic cancer was higher among males than females (62.4% vs 37.6%, respectively). Patients typically had a history of hypertension (30.8%), diabetes (21.6%), and cholangitis (20.2%). Abdominal pain (51.6%), abdominal distension (27.1%), jaundice (20.1%), and weight loss (16.3%) were the main symptoms observed in patients with advanced pancreatic cancer in this cohort. Serum carbohydrate antigen (CA)19-9 is one of the most common tumor markers. In the present study, 2562 patients underwent first-line therapy. The median progression-free survival (PFS) for patients undergoing first-line therapy was 4.1 months. The major options for first-line therapy included gemcitabine (GEM) plus S-1 (GS/X) (23.4%), nab-paclitaxel plus GEM (AG) (18.1%), oxaliplatin, irinotecan, and leucovorin-modulated fluorouracil (FOLFIRINOX; 11.9%), nab-paclitaxel plus S-1 (AS) (8.9%), and GEM combined with oxaliplatin/cisplatin (GEMOX/GP) (7.6%). The AS and GS/X regimens were associated with the highest PFS rates.Conclusion:This is the first study to report multicenter, real-world data regarding advanced pancreatic cancer in China. Results revealed that real-world treatment options differed from guideline recommendations, and PFS was shorter than that in previously reported data. Improving intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recommended.

引用

页码：1 / 9

页数：9

共 59 条

[1] CA19-9 for detecting recurrence of pancreatic cancer [J].

Azizian, Azadeh ;

Ruehlmann, Felix ;

Krause, Tanja ;

Bernhardt, Markus ;

Jo, Peter ;

Koenig, Alexander ;

Kleiss, Mathias ;

Leha, Andreas ;

Ghadimi, Michael ;

Gaedcke, Jochen .

SCIENTIFIC REPORTS, 2020, 10 (01)

[2] Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 [J].

Berlin, JD ;

Catalano, P ;

Thomas, JP ;

Kugler, JW ;

Haller, DG ;

Benson, AB .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) :3270-3275

[3] Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium [J].

Bosetti, C. ;

Rosato, V. ;

Li, D. ;

Silverman, D. ;

Petersen, G. M. ;

Bracci, P. M. ;

Neale, R. E. ;

Muscat, J. ;

Anderson, K. ;

Gallinger, S. ;

Olson, S. H. ;

Miller, A. B. ;

Bueno-de-Mesquita, H. Bas ;

Scelo, G. ;

Janout, V. ;

Holcatova, I. ;

Lagiou, P. ;

Serraino, D. ;

Lucenteforte, E. ;

Fabianova, E. ;

Ghadirian, P. ;

Baghurst, P. A. ;

Zatonski, W. ;

Foretova, L. ;

Fontham, E. ;

Bamlet, W. R. ;

Holly, E. A. ;

Negri, E. ;

Hassan, M. ;

Prizment, A. ;

Cotterchio, M. ;

Cleary, S. ;

Kurtz, R. C. ;

Maisonneuve, P. ;

Trichopoulos, D. ;

Polesel, J. ;

Duell, E. J. ;

Boffetta, P. ;

La Vecchia, C. .

ANNALS OF ONCOLOGY, 2014, 25 (10) :2065-2072

[4] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[5] Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer [J].

Carrato, Alfredo ;

Melisi, Davide ;

Prager, Gerald ;

Westphalen, Christoph B. ;

Ferreras, Anabel ;

D'Esquermes, Nathalie ;

Taieb, Julien ;

Mercade, Teresa M. .

FUTURE ONCOLOGY, 2021, 17 (15) :1843-1854

[6] Cancer Statistics in China, 2015 [J].

Chen, Wanqing ;

Zheng, Rongshou ;

Baade, Peter D. ;

Zhang, Siwei ;

Zeng, Hongmei ;

Bray, Freddie ;

Jemal, Ahmedin ;

Yu, Xue Qin ;

He, Jie .

CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132

[7] Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review [J].

Chiorean, Elena Gabriela ;

Cheung, Winston Y. ;

Giordano, Guido ;

Kim, George ;

Al-Batran, Salah-Eddin .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11

[8] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

[9] Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer [J].

Dreyer, Stephan B. ;

Upstill-Goddard, Rosie ;

Paulus-Hock, Viola ;

Paris, Clara ;

Lampraki, Eirini-Maria ;

Dray, Eloise ;

Serrels, Bryan ;

Caligiuri, Giuseppina ;

Rebus, Selma ;

Plenker, Dennis ;

Galluzzo, Zachary ;

Brunton, Holly ;

Cunningham, Richard ;

Tesson, Mathias ;

Nourse, Craig ;

Bailey, Ulla-Maja ;

Jones, Marc ;

Moran-Jones, Kim ;

Wright, Derek W. ;

Duthie, Fraser ;

Oien, Karin ;

Evers, Lisa ;

McKay, Colin J. ;

McGregor, Grant A. ;

Gulati, Aditi ;

Brough, Rachel ;

Bajrami, Ilirjana ;

Pettitt, Stephan ;

Dziubinski, Michele L. ;

Candido, Juliana ;

Balkwill, Frances ;

Barry, Simon T. ;

Grutzmann, Robert ;

Rahib, Lola ;

Johns, Amber ;

Pajic, Marina ;

Froeling, Fieke E. M. ;

Beer, Phillip ;

Musgrove, Elizabeth A. ;

Petersen, Gloria M. ;

Ashworth, Alan ;

Frame, Margaret C. ;

Crawford, Howard C. ;

Simeone, Diane M. ;

Lord, Chris ;

Mukhopadhyay, Debabrata ;

Pilarsky, Christian ;

Tuveson, David A. ;

Cooke, Susanna L. ;

Jamieson, Nigel B. .

GASTROENTEROLOGY, 2021, 160 (01) :362-+

[10] Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium [J].

Goggins, Michael ;

Overbeek, Kasper Alexander ;

Brand, Randall ;

Syngal, Sapna ;

Del Chiaro, Marco ;

Bartsch, Detlef K. ;

Bassi, Claudio ;

Carrato, Alfredo ;

Farrell, James ;

Fishman, Elliot K. ;

Fockens, Paul ;

Gress, Thomas M. ;

Van Hooft, Jeanin E. ;

Hruban, R. H. ;

Kastrinos, Fay ;

Klein, Allison ;

Lennon, Anne Marie ;

Lucas, Aimee ;

Park, Walter ;

Rustgi, Anil ;

Simeone, Diane ;

Stoffel, Elena ;

Vasen, Hans F. A. ;

Cahen, Djuna L. ;

Canto, Marcia Irene ;

Bruno, Marco ;

Arcidiacono, Paolo Giorgio ;

Ashida, Reiko ;

Ausems, Margreet ;

Besselink, Marc ;

Biermann, Katharina ;

Bonsing, Bert ;

Brentnall, Teri ;

Chak, Amitabh ;

Early, Dayna ;

Fernandez-Del Castillo, Carloz ;

Frucht, Harold ;

Furukawa, Toru ;

Gallinger, Steven ;

Geurts, Jennifer ;

Koerkamp, Bas Groot ;

Hammel, Pascal ;

Hes, Frederik ;

Iglesias-Garcia, Julio ;

Kamel, Ihab ;

Kitano, Masayuki ;

Kloppel, Gunter ;

Krak, Nanda ;

Kurtz, Robert ;

Kwon, Richard .

GUT, 2020, 69 (01) :7-17

← 1 2 3 4 5 6 →